CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -2.06: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
923.79MUSDvs all stocks (USD)
Revenue (TTM)
196.12MUSDvs all stocks (USD)
Profit Margin
-34.32%vs Biotechnology peers
Beta
0.5980xvs all stocks
52-Week Change
17.07%vs all stocks
Market Capitalization
923.79MUSDvs all stocks (USD)
Enterprise Value
720.62MUSDvs all stocks (USD)
Forward P/E
23.67xvs Biotechnology peers
Price to Sales (TTM)
4.65xvs Biotechnology peers
Price to Book (MRQ)
3.98xvs Biotechnology peers
Enterprise to Revenue
3.67xvs Biotechnology peers
Enterprise to EBITDA
-20.82xvs Biotechnology peers
Gross Margin
96.74%vs Biotechnology peers
Profit Margin
-34.32%vs Biotechnology peers
Operating Margin
-0.46%vs Biotechnology peers
Return on Assets (TTM)
-4.00%vs Biotechnology peers
Return on Equity (TTM)
-27.07%vs Biotechnology peers
Revenue (TTM)
196.12MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2940USDUpdated Jul 19, 2026Quarterly Revenue Growth
30.90%vs Biotechnology peers
Gross Profit (TTM)
119.57MUSDvs all stocks (USD)
EBITDA (TTM)
-34.61MUSDvs all stocks (USD)
Net Income (TTM)
-67.31MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
30.89%vs Biotechnology peers
Operating Cash Flow (TTM)
-125.96MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-92.14MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
183.88MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.75MUSDFY2025 · Dec 31, 2025Gross Profit
179.14MUSDFY2025 · Dec 31, 2025Operating Income
-51.55MUSDvs all stocks (USD)
Pre-tax Income
-83.50MUSDFY2025 · Dec 31, 2025Net Income
-83.50MUSDFY2025 · Dec 31, 2025EBIT
-50.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-32.61MUSDFY2025 · Dec 31, 2025Research & Development
71.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
159.26MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
32.66MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1300USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
666.66MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
666.66MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-83.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-118.43MUSDFY2025 · Dec 31, 2025Free Cash Flow
-118.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
79.44MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-83.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.75MUSDFY2025 · Dec 31, 2025Other Non-cash Items
20.02MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-377.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.66MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-85.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
-49.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-304.42MUSDFY2025 · Dec 31, 2025Sale of Investments
411.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
641.03MSharesUpdated Jul 19, 2026Float Shares
535.70MSharesUpdated Jul 19, 2026Shares Short
80.22MSharesUpdated Jul 19, 2026Short Ratio
5.41daysvs all stocks
Short % of Shares Outstanding
12.51%vs all stocks
% Held by Insiders
0.08%vs all stocks
% Held by Institutions
79.65%vs all stocks
Total Cash (MRQ)
312.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4870USDUpdated Jul 19, 2026Total Debt (MRQ)
122.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5328xvs Biotechnology peers
Current Ratio (MRQ)
6.78xvs Biotechnology peers
Book Value per Share (MRQ)
0.3570USDUpdated Jul 19, 2026Total Assets
570.54MUSDvs all stocks (USD)
Total Current Assets
520.27MUSDFY2025 · Dec 31, 2025Total Liabilities
344.67MUSDFY2025 · Dec 31, 2025Total Non-current Assets
50.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
233.13MUSDFY2025 · Dec 31, 2025Total Current Liabilities
111.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
77.56MUSDFY2025 · Dec 31, 2025Other Short-term Investments
280.36MUSDFY2025 · Dec 31, 2025Accounts Receivable
36.99MUSDFY2025 · Dec 31, 2025Inventory
116.64MUSDFY2025 · Dec 31, 2025Accounts Payable
11.26MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
17.45MUSDFY2025 · Dec 31, 2025Long-term Debt
120.99MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
112.13MUSDFY2025 · Dec 31, 2025Common Stock (Book)
640.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.86BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
225.87MUSDvs all stocks (USD)
52-Week Low
1.04USDUpdated Jul 19, 202652-Week High
2.01USDUpdated Jul 19, 202652-Week Change
17.07%vs all stocks
Beta
0.5980xvs all stocks
50-Day MA
1.32USDUpdated Jul 19, 2026200-Day MA
1.39USDUpdated Jul 19, 2026Avg 10-Day Volume
10.08MSharesUpdated Jul 19, 2026Avg 30-Day Volume
13.37MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.1100USDUpdated Jul 19, 2026Other Income / Expense
-17.41MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.97Profit Margin: -0.34
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.78Altman Z-Score: -2.06
Financial Health
Altman Z-Score -2.06: distress zoneCritical
Altman Z-Score: -2.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Eos Energy Enterprises Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC